Stockscreener 앱 받기
29.64
2.98%
-0.91
Newamsterdam Pharma Company Nv 주식(NAMS)의 최신 뉴스
How EMA’s Positive CHMP Opinion on Ubeslo and Evlarco at NewAmsterdam Pharma (NAMS) Has Changed Its Investment Story - simplywall.st
EQS-News: NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)boerse.de - boerse.de
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - recnews.it
Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) - marketscreener.com
NewAmsterdam Pharma Wins EMA Backing for Obicetrapib Therapies - TipRanks
NewAmsterdam Pharma gets positive CHMP opinion for obicetrapib-based Ubeslo and Evlarco, EC decision due 2H26 - TradingView
Europe's drug committee recommends two NewAmsterdam cholesterol treatments - Stock Titan
NewAmsterdam and Menarini Receive Positive CHMP Opinion for Ubeslo and Evlarco - Intellectia AI
NewAmsterdam Pharma Company (NAMS) Q1 2026 earnings summary - Quartr
NewAmsterdam Pharma Announces COO Transition and Advisory Role - TipRanks
NewAmsterdam Pharma's COO Douglas Kling to Leave for CEO Role at Another Clinical-Stage Biotech Company - Kalkine Media
Form 4 NewAmsterdam Pharma Co N.V. For: 22 July By Investing.com - Investing.com Nigeria
NewAmsterdam Pharma (NAMS) COO Douglas Kling to step down Aug 14 - Stock Titan
NewAmsterdam Pharma (NAMS) CAO trades 105000 shares under 10b5-1 plan - Stock Titan
NewAmsterdam Pharma Company N.V. Announces Resignation of Douglas Kling from Chief Operating Officer, Effective August 14, 2026 - marketscreener.com
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – SWB:KH6 - TradingView
NewAmsterdam Pharma Company (NAMS) Citi Annual Global Healthcare Conference 2025 summary - Quartr
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data By Investing.com - Investing.com Nigeria
Jefferies reiterates NewAmsterdam Pharma stock rating ahead of data - Investing.com
Responsive Playbooks and the NAMS Inflection - Stock Traders Daily
NewAmsterdam Pharma publishes obicetrapib Alzheimer’s prevention research presentation - Bitget
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – MUN:KH6 - TradingView
Price-Driven Insight from (NAMSW) for Rule-Based Strategy - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Drops 5.6% as Selling Pressure IntensifiesLarge Cap Trends - dars.gov.et
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Dips Amidst Sector Rotation; Key Support in FocusFundamental Weighted - dars.gov.et
NewAmsterdam Pharma Company (NAMS) Jefferies Global Healthcare Conference 2025 summary - Quartr
NewAmsterdam Pharma to Present Obicetrapib Alzheimer’s Data - t.co
NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus - Sahm
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
NAMSNewAmsterdam Pharma Company NV Latest SEC Filings - Finviz
(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NewAmsterdam Pharma awards stock incentives to four new hires - Stock Titan
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. - TradingView
NewAmsterdam Pharma puts obicetrapib in Alzheimer’s spotlight at AAIC 2026 - Stock Titan
Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Understanding the Setup: (NAMS) and Scalable Risk - Stock Traders Daily
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS) - TradingView
NAMS Forecast — Price Target — Prediction for 2027 - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6) - TradingView
Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC) - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Slides 2.76% as Stock Tests Key Support LevelsRounding Bottom - dars.gov.et
Price to earnings forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares - Stock Titan
Price to earnings forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
Breakeven On The Horizon For NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Moomoo
NewAmsterdam Pharma Company NV (NAMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company (NAMS) Proxy filing Summary - Quartr
NAMS News | NEWAMSTERDAM PHARMA CO NV (NASDAQ:NAMS) - ChartMill
NewAmsterdam Pharma Company NV (NAMSW) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
0.46%
0.84%
자본화:
|
볼륨(24시간):